• Lantern Pharma disclosed a successful FDA Type C interaction that cleared key protocol changes for its Phase 2 HARMONIC trial of LP-300 in never-smokers with advanced non-small cell lung cancer.
• Early trial results have already been presented, supporting a sharper focus on a specific EGFR mutation where the regimen has shown a more consistent benefit signal than in broader EGFR-mutant groups.
• The updated plan shifts the study to a single-arm design, aiming to speed enrollment and generate a clearer data set for regulators and potential partners.
• The company also plans to extend treatment duration in the trial, citing prior experience that supports continued dosing without meaningfully changing the tolerability profile.
• Additional clinical updates from the amended study are expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605190730BIZWIRE_USPR_____20260519_BW628990) on May 19, 2026, and is solely responsible for the information contained therein.